🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Clinical Pre-screening Protocol for Ovarian Cancer

Recruitingn/aAges 18 Years - anyFemaleAllarity Therapeutics
NCT03877796 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with histological confirmed epithelia ovarian cancer * Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible. * Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting * FFPE tumor tissue available Exclusion Criteria: * Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy. * Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator
💊

What it tests

  • Drug Response Predictor® (DRP)
📍

Where

9 sites
Moffitt Cancer Center
Tampa, United States
Emory Winship Cancer Institute
Atlanta, United States
University of New Mexico Comprehensive Cancer
Albuquerque, United States
The Blavatnik Family-Chelsea Medical Center at Mount Sinai
New York, United States
OU Health Stephenson Cancer Center
Oklahoma City, United States
University Medical Center Cancer Center
Lubbock, United States
Swedish Center for Research and Innovation
Seattle, United States
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom

…and 1 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy